Publications by authors named "Karen Xia"
Clin J Oncol Nurs
September 2024
Article Synopsis
- Amivantamab is an antibody approved for advanced non-small cell lung cancer with specific genetic variants, but it often causes skin-related side effects due to its effects on the epidermal growth factor receptor (EGFR).
- A study analyzed how often and severely patients experienced these skin issues, focusing on conditions like rash and paronychia, after their disease progressed on platinum chemotherapy.
- Out of 380 patients studied, a significant 78% experienced skin-related side effects, with paronychia and various rashes being the most common; healthcare providers worked together to manage these issues through dose adjustments and patient education.
